RANI
Rani Therapeutics Holdings IncKey Statistics
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings Inc. is at the forefront of biotechnology innovation, transforming injectable therapies with its proprietary RaniPill™ technology that allows for oral delivery of biologics. This cutting-edge platform addresses significant patient adherence challenges, aiming to enhance treatment efficacy while meeting the rising demand for non-invasive therapeutic options. With a robust and diverse pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned to disrupt traditional drug delivery paradigms. The company's commitment to research and development, coupled with strategic collaborations, underpins its potential for significant growth and impactful contributions to the pharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $3.17M |
| Gross Profit (TTM) | $3.17M |
| EBITDA | $-33.83M |
| Operating Margin | -488.20% |
| Return on Equity | -240.00% |
| Return on Assets | -57.00% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.34 |
| Price-to-Book | 3.76 |
| Price-to-Sales (TTM) | 42.21 |
| EV/Revenue | 21.28 |
| EV/EBITDA | -1.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 893.00% |
| Shares Outstanding | $99.91M |
| Float | $70.78M |
| % Insiders | 5.63% |
| % Institutions | 47.44% |
Historical Volatility
Volatility is currently expanding